Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

Condition:   Elevated Low-Density Lipoprotein Cholesterol Interventions:   Drug: SNK-396 - SAD cohort;   Drug: SNK-396 - MAD Cohort Sponsors:   Syneos Health;   SynerK Pharmatech (Suzhou) Limited Recruiting

Source: ClinicalTrials.gov - June 9, 2023 Category: Research Source Type: clinical trials